COVID/SARS CoV2 Rapid Research Reports #5
January 26 - 27, 2021 Virtual
Abstract Deadline: January 5, 2021
Registration Deadline: January 22 @ 4:00 pm EST


Hung Fan, University of California Irvine
Adrian Hayday, King's College London, UK
Susan Weiss, University of Pennsylvania Perelman School of Medicine
Volker Thiel, University of Bern, Switzerland

Almost 100 million cases and over 2 million deaths due to COVID, and economic devastation on a global scale, the global scientific community will come together for the fifth meeting in the COVID19/SARS CoV2 Rapid Research Reports series, bringing together expert scientists on the forefront of COVID research into viral origins & variation, virus biology, host response, and antivirals & vaccines. Previous meetings in the series were held in June, July, August and November 2020. The series is designed to stimulate ideas and collaborations among scientists with the goal of hastening a solution to vanquish this worldwide disease.

Sessions & Confirmed Speakers (COVID-R3-#5) Times posted in US Eastern Standard Time

Session I: Host-virus Interactions/Structure
Tuesday, January 26 - 9:30 am EST
Co-Chairs: Marjolein Kikkert, Leiden University Medical Center & Tony Schountz, Colorado State University

Neil Ferguson, Imperial College London, United Kingdom - Epidemiology of B.1.1.7
Hugo Zeberg, Karolinska Institute - Neandertal Gene Variants and Risk of Severe COVID-19
Bill Schneider, Rockefeller UniversityCRISPR screens identify TMEM41B as a pan-coronavirus host factor
Annika Kratzel, Universität BernA Genome-wide CRISPR Screen Identifies Interactors of the Autophagy Pathway as Conserved Coronavirus Targets
Nenad Ban, ETH Zurich Structural Basis of SARS-CoV-2 Translational Shutdown and Programmed Ribosomal Frameshifting
Yong Xiong, Yale University Nonstructural protein 1 of SARS-CoV-2 is apotent pathogenicity factor redirecting host protein synthesis machinery towardviral RNA

Session II: Coronavirus Biology
Tuesday, January 26 - 2:00 pm EST
Co-Chairs: Vineet Menachery, University of Texas Medical Branch & Stephanie Pfaender, Ruhr-Universität Bochum

Luca Zaeck, Friedrich Loeffler Institute - 3D Reconstruction of SARS-CoV-2 Infection in Ferrets Emphasizes Focal Infection Pattern in the Upper Respiratory Tract
Walther Mothes, Yale University - Imaging SARS-CoV-2 across multiple scales from animals to single molecules
Nihal Altan-Bonnet, National Institutes of Health - Sneaking Out With The Trash: How Coronaviruses Exit Cells
Ralph Baric, University of North Carolina - SARS-CoV2 and D614G Emergence, Transmission and Evolution
Bin Zhou, Centers for Disease Control and PreventionSARS-CoV-2 Spike 614G Variant Confers Enhanced Replication and Transmission

Session III: Pathogenesis & The Immune Response
Wednesday, January 27 - 9:30 am EST
Co-Chairs: Paul Klenerman, Medawar/University of Oxford & Francesca Di Rosa, Inst Molecular Biology & Pathology (CNR), Rome

Yoko Hamazaki, Kyoto University The Impact of Aging on SARS-CoV-2 Reactive T Cells
Florian Krammer, Icahn School of Medicine at Mount Sinai Antibody Responses to the SARS-CoV-2 Spike
Antonio Bertoletti, Duke-NUS Medical School - Profile of SARS-CoV2 T Cell Response in Asymptomatic Infection
Purvesh Khatri, Stanford University - Learning Across Viruses and Preparing for the Next Pandemic
James Heath, Institute for Systems Biology - Deep, Longitudinal Analyses of 200 COVID-19 Patients from Clinical Diagnosis to Disease Recovery
Aaron Ring, Yale UniversityAutoantibodies in COVID-19

Session IV: Vaccines/Antivirals
Wednesday, January 27 - 2:00 pm EST
Co-Chairs: Matthew Frieman, University of Maryland & Lisa Gralinski, University of North Carolina

Frances Lund, University of Alabama at Birmingham - Development of Mucosal Vaccines for SARS-CoV-2
Sean Whelan, Washington University  Vesicular Stomatitis Virus as a Bullet Against COVID
John Chodera, Memorial Sloan Kettering Cancer Center The COVID Moonshot: Closing in on an Orally Bioavailable Non-peptidomimetic Small Molecule Inhibitor of SARS-CoV-2 Mpro with an Open Science Collaboration
Christopher Schofield, University of Oxford Mechanistic and Inhibition Studies on Mpro from SARS-CoV-2
Matteo Porotto, Columbia University Fusion Inhibitory Lipopeptide Prevents SARS-CoV-2 Infection In Vivo


Late Virtual COVID-R3 #5 Package: $129

Discount Virtual COVID-R3 #5 Packages (Previous Attendees Only/Email Alicia Franco for Discount Pricing):
Attended 1 prior CSHL COVID meeting: $85
Attended 2 prior CSHL COVID meetings: $80
Attended all 3 prior CSHL COVID meetings: $75

(All new registrants may register for possible future COVID-R3 conferences for $85/conference)

Virtual Attendance packages include access to online Zoom-based oral sessions with live Q&A and access to the video archive on the Leading Strand for ~twelve weeks following each meeting. For registration & discount questions please reach Alicia Franco.

Virtual 2 day live meeting + 12 weeks archive access

Card image cap
~28 talks / 4 sessions
(late am/early pm)
~12 total hours with interactive Q&A
Card image cap
Virtual posters with dedicated slack channels for each poster
Card image cap
Virtual Social Events~
Opening Icebreaker / Closing Social

Card image cap
Twitter for meeting news & general comments

Social Media   

The designated hashtag for this meeting is #cshlCOVID. Note that you must obtain permission from an individual presenter before live-tweeting or discussing his/her talk, poster, or research results on social media. Click the Policies tab above to see our full Confidentiality & Reporting Policy.